Kevin DeGeeter
Stock Analyst at Ladenburg Thalmann
(2.95)
# 1,850
Out of 5,090 analysts
46
Total ratings
40%
Success rate
65.56%
Average return
Main Sectors:
Stocks Rated by Kevin DeGeeter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NXTC NextCure | Upgrades: Buy | $18 | $12.34 | +45.93% | 1 | Nov 7, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Buy | $15 | $11.00 | +36.36% | 2 | Jul 8, 2025 | |
| CRDF Cardiff Oncology | Initiates: Buy | $19 | $2.11 | +800.47% | 1 | Jul 8, 2025 | |
| NVCR NovoCure | Initiates: Buy | $30 | $12.11 | +147.73% | 4 | Jul 8, 2025 | |
| ANTX AN2 Therapeutics | Initiates: Outperform | $22 | $1.10 | +1,900.00% | 1 | Apr 19, 2022 | |
| PSNL Personalis | Maintains: Outperform | $30 → $24 | $9.56 | +151.05% | 4 | Feb 25, 2022 | |
| FLGT Fulgent Genetics | Maintains: Outperform | $141 → $125 | $27.79 | +349.80% | 3 | Jan 25, 2022 | |
| MDXH MDxHealth | Initiates: Outperform | $18 | $3.60 | +400.00% | 1 | Nov 29, 2021 | |
| SERA Sera Prognostics | Initiates: Outperform | $19 | $3.08 | +516.88% | 1 | Nov 19, 2021 | |
| SPRO Spero Therapeutics | Downgrades: Perform | n/a | $2.26 | - | 1 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $79 | $198.84 | -60.18% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $161 → $155 | $101.06 | +53.37% | 2 | Jul 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $9.72 | - | 2 | Jun 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $10.42 | +139.92% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,800 | $5.25 | +34,185.71% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $36.23 | - | 2 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $5.05 | - | 1 | Jan 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.32 | - | 4 | Dec 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $1,500 | $3.77 | +39,687.80% | 1 | Jul 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.68 | +53,471.43% | 1 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $6.91 | - | 2 | Aug 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $165 | $13.07 | +1,162.43% | 1 | Jun 6, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $225 | $220.36 | +2.11% | 1 | Apr 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $7.09 | - | 5 | Feb 8, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.83 | - | 2 | Jan 4, 2017 |
NextCure
Nov 7, 2025
Upgrades: Buy
Price Target: $18
Current: $12.34
Upside: +45.93%
ORIC Pharmaceuticals
Jul 8, 2025
Initiates: Buy
Price Target: $15
Current: $11.00
Upside: +36.36%
Cardiff Oncology
Jul 8, 2025
Initiates: Buy
Price Target: $19
Current: $2.11
Upside: +800.47%
NovoCure
Jul 8, 2025
Initiates: Buy
Price Target: $30
Current: $12.11
Upside: +147.73%
AN2 Therapeutics
Apr 19, 2022
Initiates: Outperform
Price Target: $22
Current: $1.10
Upside: +1,900.00%
Personalis
Feb 25, 2022
Maintains: Outperform
Price Target: $30 → $24
Current: $9.56
Upside: +151.05%
Fulgent Genetics
Jan 25, 2022
Maintains: Outperform
Price Target: $141 → $125
Current: $27.79
Upside: +349.80%
MDxHealth
Nov 29, 2021
Initiates: Outperform
Price Target: $18
Current: $3.60
Upside: +400.00%
Sera Prognostics
Nov 19, 2021
Initiates: Outperform
Price Target: $19
Current: $3.08
Upside: +516.88%
Spero Therapeutics
Oct 1, 2021
Downgrades: Perform
Price Target: n/a
Current: $2.26
Upside: -
Aug 24, 2021
Maintains: Outperform
Price Target: $75 → $79
Current: $198.84
Upside: -60.18%
Jul 29, 2021
Maintains: Outperform
Price Target: $161 → $155
Current: $101.06
Upside: +53.37%
Jun 29, 2021
Downgrades: Perform
Price Target: n/a
Current: $9.72
Upside: -
May 27, 2021
Initiates: Outperform
Price Target: $25
Current: $10.42
Upside: +139.92%
Mar 2, 2021
Initiates: Outperform
Price Target: $1,800
Current: $5.25
Upside: +34,185.71%
Jan 11, 2021
Downgrades: Perform
Price Target: n/a
Current: $36.23
Upside: -
Jan 5, 2021
Initiates: Outperform
Price Target: n/a
Current: $5.05
Upside: -
Dec 8, 2020
Downgrades: Perform
Price Target: n/a
Current: $3.32
Upside: -
Jul 1, 2020
Initiates: Outperform
Price Target: $1,500
Current: $3.77
Upside: +39,687.80%
Apr 8, 2020
Initiates: Outperform
Price Target: $900
Current: $1.68
Upside: +53,471.43%
Aug 9, 2017
Upgrades: Buy
Price Target: n/a
Current: $6.91
Upside: -
Jun 6, 2017
Initiates: Buy
Price Target: $165
Current: $13.07
Upside: +1,162.43%
Apr 12, 2017
Initiates: Buy
Price Target: $225
Current: $220.36
Upside: +2.11%
Feb 8, 2017
Upgrades: Neutral
Price Target: n/a
Current: $7.09
Upside: -
Jan 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $1.83
Upside: -